STOCK TITAN

[144] CYTOKINETICS INC SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

CYTOKINETICS, INC. (CYTK) Form 144 notice reports a proposed sale of 6,695 common shares valued at $360,793.55, to be sold through Morgan Stanley Smith Barney on 09/30/2025 on NASDAQ. The shares were acquired as restricted stock units on 10/01/2021 from the issuer and payment was recorded as N/A. The filing also discloses recent 10b5-1 sales by the reported person: 6,756 shares sold on 09/02/2025 for $337,800.00. The filer affirms no undisclosed material adverse information and references Rule 10b5-1 trading plan requirements.

CYTOKINETICS, INC. (CYTK) Form 144 avviso riporta una proposta di vendita di 6.695 azioni ordinarie per un valore di 360.793,55$, da vendere tramite Morgan Stanley Smith Barney il 30/09/2025 sul NASDAQ. Le azioni sono state acquisite come unità azionarie vincolate (RSU) il 01/10/2021 dall'emittente e il pagamento è stato registrato come N/A. La presentazione segnala anche vendite recenti 10b5-1 da parte della persona dichiarata: 6.756 azioni vendute il 02/09/2025 per 337.800,00$. Il dichiarante afferma di non possedere informazioni materiali sfavorevoli non divulgate e fa riferimento ai requisiti del piano di negoziazione 10b5-1.

CYTOKINETICS, INC. (CYTK) aviso de Formulario 144 reporta una venta propuesta de 6.695 acciones ordinarias valoradas en 360.793,55$, para ser vendidas a través de Morgan Stanley Smith Barney el 30/09/2025 en NASDAQ. Las acciones fueron adquiridas como unidades de acciones restringidas (RSU) el 01/10/2021 del emisor y el pago se registró como N/A. La presentación también divulga ventas recientes 10b5-1 por la persona reportada: 6.756 acciones vendidas el 02/09/2025 por 337.800,00$. El presentante afirma no poseer información material adversa no divulgada y hace referencia a los requisitos del plan de negociación 10b5-1.

CYTOKINETICS, INC. (CYTK) Form 144 공지6,695 주의 보통주가 360,793.55달러로 평가되어 NASDAQ의 2025-09-30에 모건 스탠리 스미스 바니를 통해 매도될 예정임을 보도합니다. 주식은 발행사로부터 제한 주식 단위(RSU)2021-10-01에 취득되었으며 지급은 N/A로 기록되었습니다. 보고서는 또한 보고 대상자의 최근 10b5-1 매매를 공개합니다: 6,756주가 2025-09-02에 매도되어 337,800.00달러를 기록했습니다. 제출자는 비공개의 중요한 부정 정보를 가지고 있지 않다고 확인하며 10b5-1 거래 계획 요건을 언급합니다.

CYTOKINETICS, INC. (CYTK) Formulaire 144 avis rapporte une vente proposée de 6.695 actions ordinaires d'une valeur de 360.793,55$, à vendre par Morgan Stanley Smith Barney le 30/09/2025 sur le NASDAQ. Les actions ont été acquises sous forme d'unités d'actions restreintes (RSU) le 01/10/2021 de l'émetteur et le paiement a été enregistré comme N/A. Le dépôt divulgue également des ventes récentes 10b5-1 par la personne déclarée : 6.756 actions vendues le 02/09/2025 pour 337.800,00$. Le déposant affirme ne pas détenir d'informations matérielles défavorables non divulguées et fait référence aux exigences du plan de trading 10b5-1.

CYTOKINETICS, INC. (CYTK) Form 144 Mitteilung berichtet von einem vorgeschlagenen Verkauf von 6.695 Stammaktien im Wert von 360.793,55$, der über Morgan Stanley Smith Barney am 30.09.2025 an der NASDAQ verkauft werden soll. Die Aktien wurden am 01.10.2021 vom Emittenten als eingeschränkte Aktien (RSU) erworben und die Zahlung wurde als N/A verzeichnet. Die Einreichung gibt auch jüngste 10b5-1-Verkäufe der gemeldeten Person bekannt: 6.756 Aktien am 02.09.2025 für 337.800,00$. Der Antragsteller bestätigt, dass keine nicht offengelegten materiellen negativen Informationen vorliegen, und verweist auf die Anforderungen des 10b5-1-Handelsplans.

CYTOKINETICS, INC. (CYTK) إشعار النموذج 144 يذكر بيعًا مقترحًا لـ 6,695 أسهم عادية بقيمة 360,793.55$، ليُباع عبر مورجان ستانلي سميث بارني في 30/09/2025 في ناسداك. تم الاستحواذ على الأسهم كـ وحدات أسهم مقيدة (RSU) في 01/10/2021 من المصدر وُسجل الدفع كـ N/A. كما يكشف الإبلاغ عن مبيعات 10b5-1 حديثة من الشخص المعلن: 6,756 أسهم مُباعة في 02/09/2025 بمبلغ 337,800.00 دولار. يؤكد المبلغ عدم وجود معلومات سلبية مادية غير مُعلنة ويشير إلى متطلبات خطة التداول 10b5-1.

CYTOKINETICS, INC. (CYTK) 表格 144 通知 报告拟议出售 6,695 股普通股,估值为 360,793.55 美元,将于 2025-09-30 通过摩根士丹利史密斯巴尼在纳斯达克出售。该等股份于 2021-10-01 以受限股票单位(RSU)的形式由发行方取得,支付记录为 N/A。该备案还披露了申报人最近的 10b5-1 交易:6,756 股于 2025-09-02 出售,金额为 337,800.00 美元。申报人确认无未披露的重大不利信息,并提及 10b5-1 交易计划的要求。

Positive
  • Proper disclosure of proposed sale under Rule 144 with broker, share count, value, and planned sale date
  • Origin of shares identified as restricted stock units acquired 10/01/2021, showing provenance of holdings
  • Recent 10b5-1 sale disclosed (6,756 shares on 09/02/2025 for $337,800.00), indicating consistent reporting
Negative
  • Insider selling activity totaling ~13,451 shares disclosed across planned and recent sales, which could be interpreted negatively by some investors
  • No information provided on the proportion of insider holdings remaining or relationship of the seller to the issuer beyond the form text

Insights

TL;DR: Insider intends to sell ~6.7k shares (~$361k) via broker; recent 10b5-1 sales of similar size occurred earlier in September.

This Form 144 documents a proposed sale under Rule 144 of 6,695 common shares acquired as RSUs on 10/01/2021, to be executed through Morgan Stanley Smith Barney on NASDAQ on 09/30/2025, with an aggregate market value of $360,793.55. The filing also reports a 10b5-1 sale of 6,756 shares on 09/02/2025 producing $337,800.00. From a trading-flow perspective, these are modest insider disposals relative to typical market-cap dynamics; the filing shows procedural compliance but does not include any financial performance metrics.

TL;DR: Filing indicates compliance with disclosure and 10b5-1 representation; repeated insider sales are documented but no governance breaches are stated.

The notice contains the required attestation that the seller is unaware of undisclosed material adverse information and cites Rule 10b5-1 plan adoption language. It identifies the broker and the origin of the shares as issuer-granted restricted stock units from 10/01/2021. The document does not allege any regulatory issues or governance actions; it is a routine insider sale disclosure for investor transparency.

CYTOKINETICS, INC. (CYTK) Form 144 avviso riporta una proposta di vendita di 6.695 azioni ordinarie per un valore di 360.793,55$, da vendere tramite Morgan Stanley Smith Barney il 30/09/2025 sul NASDAQ. Le azioni sono state acquisite come unità azionarie vincolate (RSU) il 01/10/2021 dall'emittente e il pagamento è stato registrato come N/A. La presentazione segnala anche vendite recenti 10b5-1 da parte della persona dichiarata: 6.756 azioni vendute il 02/09/2025 per 337.800,00$. Il dichiarante afferma di non possedere informazioni materiali sfavorevoli non divulgate e fa riferimento ai requisiti del piano di negoziazione 10b5-1.

CYTOKINETICS, INC. (CYTK) aviso de Formulario 144 reporta una venta propuesta de 6.695 acciones ordinarias valoradas en 360.793,55$, para ser vendidas a través de Morgan Stanley Smith Barney el 30/09/2025 en NASDAQ. Las acciones fueron adquiridas como unidades de acciones restringidas (RSU) el 01/10/2021 del emisor y el pago se registró como N/A. La presentación también divulga ventas recientes 10b5-1 por la persona reportada: 6.756 acciones vendidas el 02/09/2025 por 337.800,00$. El presentante afirma no poseer información material adversa no divulgada y hace referencia a los requisitos del plan de negociación 10b5-1.

CYTOKINETICS, INC. (CYTK) Form 144 공지6,695 주의 보통주가 360,793.55달러로 평가되어 NASDAQ의 2025-09-30에 모건 스탠리 스미스 바니를 통해 매도될 예정임을 보도합니다. 주식은 발행사로부터 제한 주식 단위(RSU)2021-10-01에 취득되었으며 지급은 N/A로 기록되었습니다. 보고서는 또한 보고 대상자의 최근 10b5-1 매매를 공개합니다: 6,756주가 2025-09-02에 매도되어 337,800.00달러를 기록했습니다. 제출자는 비공개의 중요한 부정 정보를 가지고 있지 않다고 확인하며 10b5-1 거래 계획 요건을 언급합니다.

CYTOKINETICS, INC. (CYTK) Formulaire 144 avis rapporte une vente proposée de 6.695 actions ordinaires d'une valeur de 360.793,55$, à vendre par Morgan Stanley Smith Barney le 30/09/2025 sur le NASDAQ. Les actions ont été acquises sous forme d'unités d'actions restreintes (RSU) le 01/10/2021 de l'émetteur et le paiement a été enregistré comme N/A. Le dépôt divulgue également des ventes récentes 10b5-1 par la personne déclarée : 6.756 actions vendues le 02/09/2025 pour 337.800,00$. Le déposant affirme ne pas détenir d'informations matérielles défavorables non divulguées et fait référence aux exigences du plan de trading 10b5-1.

CYTOKINETICS, INC. (CYTK) Form 144 Mitteilung berichtet von einem vorgeschlagenen Verkauf von 6.695 Stammaktien im Wert von 360.793,55$, der über Morgan Stanley Smith Barney am 30.09.2025 an der NASDAQ verkauft werden soll. Die Aktien wurden am 01.10.2021 vom Emittenten als eingeschränkte Aktien (RSU) erworben und die Zahlung wurde als N/A verzeichnet. Die Einreichung gibt auch jüngste 10b5-1-Verkäufe der gemeldeten Person bekannt: 6.756 Aktien am 02.09.2025 für 337.800,00$. Der Antragsteller bestätigt, dass keine nicht offengelegten materiellen negativen Informationen vorliegen, und verweist auf die Anforderungen des 10b5-1-Handelsplans.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 for CYTK disclose about the proposed sale?

The filing discloses a proposed sale of 6,695 common shares valued at $360,793.55 to be executed on 09/30/2025 through Morgan Stanley Smith Barney on NASDAQ.

How were the shares being sold by CYTK acquired?

The shares were acquired as Restricted Stock Units (RSUs) from the issuer on 10/01/2021.

Has the filer sold any CYTK shares recently?

Yes. The filing reports a 10b5-1 sale of 6,756 shares on 09/02/2025 for $337,800.00.

Who is the broker handling the proposed sale?

The proposed sale is to be handled by Morgan Stanley Smith Barney LLC Executive Financial Services at the New York address listed in the filing.

Does the filer state any undisclosed material information?

By signing the notice, the person represents they do not know any material adverse information not publicly disclosed regarding the issuer.

Are the shares being sold part of a trading plan?

The filing references Rule 10b5-1 language and discloses a prior 10b5-1 sale, but it does not explicitly state the adoption date of a trading plan in the provided content.
Cytokinetics Inc

NASDAQ:CYTK

CYTK Rankings

CYTK Latest News

CYTK Latest SEC Filings

CYTK Stock Data

6.74B
117.21M
0.69%
117.95%
11.56%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO